




BioReperia

Changing the gameplan for cancer patients



THE VISION

BioReperia's vision
is to radically
reduce
cancer
mortality




BioReperia is ready to revolutionize the basis for how we treat cancer patients

ZTX[®] finds the most
effective treatments for
each cancer patient
within 5 days



THE PROBLEM

Poor methods to personalize therapy leads to treatment being ineffective in **2 of 3 cancer patients** today



CURRENT DIAGNOSTICS

GENOMICS



PATIENTS REACHED

100%


< 10%

ACCURACY PREDICTING TREATMENT OUTCOME: **Not predictive**

~50%

New methods that reach all patients, are sensitive, specific, fast and cost-effective are **urgently needed**


An in-vivo diagnostic tool to personalize treatment of cancer patients



- ✓ Identifies most efficient treatment for all patients
- ✓ Accuracy of 80% on treatment and progression prediction
- ✓ Results within 5 days
- ✓ Highly cost-effective
- ✓ CE-marked

BUSINESS MODEL

Sell ZTX[®]PREDICT to 4 relevant stakeholder segments



STAKEHOLDER

PARTNER

Clinics



Private individuals

Undisclosed due to GDPR regulations

Pharmaceutical companies



Clinical service or product providers



Potentially in the future:



ABOUT BIOREPERIA


Milestones

- ✓ Approved CE certification of ZTX®PREDICT
- ✓ An implemented QMS (ISO13485 and ISO 15189)
- ✓ Predictive capability of ZTX®PREDICT with an 80% specificity and sensitivity for beneficial outcomes to neoadjuvant cytostatic therapy in urinary bladder cancer and adjuvant cytostatic therapy in epithelial ovarian cancer.
- ✓ Automation robots developed to scale up productivity
- ✓ Previous years sales growth with 50-150% with >80% recurrent customers in >15 countries


Funding

- ✓ Raised 1.2 MEUR
- ✓ Awarded 1 MEUR in grant support

BioReperia Turnover in EUR from 2017-2023



ONE PLATFORM TWO MARKETS



KPI:s ZTX®PREDICT	
No of unique customers	5
No of orders	8
Total order value	116 k€
Average order value	17 k€

KPI:s ZTX®ONCOLEADS	
No of unique customers	72
No of orders	115
Total order value	1.7 M€
Average order value	13 k€
Recurring customers	81%

Testimonials

"The ZTX®platform has the potential to rapidly identify unique treatment opportunities with curative potential for individual patients with solid tumors that previously were only offered palliative (symptom-relieving) therapy".

... Per Sandström, Key Opinion Leader in gastrointestinal cancers

"The ZTX®platform revolutionizes oncology research by enabling precise evaluation of drug efficacy in zebrafish patient-derived xenograft models, significantly advancing personalized medicine and the development of targeted cancer therapies."

...Georgios Evangelou, Key Opinion Leader in oncology

"The zebrafish embryo model is not only a key component of anti-cancer drug discovery pipelines but also a pivotal platform for precision cancer medicine."


... Lars Bräutigam, Head of the zebrafish core facility, Karolinska Institute

ROADMAP AND MILESTONES

	2024	2025	2026	2027	2028	2030
Milestones	<ul style="list-style-type: none"> Hospital customers 	<ul style="list-style-type: none"> Needle biopsies Regulatory road map IP 	<ul style="list-style-type: none"> Clinical trials FDA/IVD-R Robotics implementation Clinical intervention study 	<ul style="list-style-type: none"> FDA/IVD-R approval Full automation capacity 	<ul style="list-style-type: none"> Implemented ZTX®Predict in US US sales office 	<ul style="list-style-type: none"> Approved to be used in Top 10 most prevalent solid cancers CPI for 5 diagnoses
Market	<p><i>Clinical:</i> West Europe</p> <p><i>Pre-clinical/ pharma:</i> Europe, US and Asia</p>	<p><i>Clinical:</i> West Europe, Middle East</p> <p><i>Pre-clinical/ pharma:</i> Europe, US and Asia</p>	Companion diagnostics	Licencing ZTX to partnership CROs	US sales office	Licencing to hospitals
Revenue	500k€	1.2 M€	3 M€	5 M€	8 M€	40 M€

Financials

BioReperia income statement plan in EUR



2024: 10 MSEK (1 MEUR)

- 7 MSEK is already secured
- Positive cash flow 2025
- Launch ZTX®PREDICT on the EU market for clinical treatment planning
- Prepare protocols for FDA/IVD-R study
- Needle biopsies

2026: 50 MSEK (5 MEUR)

- Grow sales of ZTX®PREDICT and ZTX®ONCOLEADS
- FDA and IVD-R approval
- Automation technology

THE TEAM

Management team



Anna Erksam, PhD,
CEO



Marie Waldén, CBO



**Marie Högvist, Lab
Manager, QA/RA**



Lasse Jensen, PhD,
CTO, Co-founder



Anna Fahlgren, PhD
Co-founder

Production team



Zaheer Ali, PhD
Lab technician



Decky Tandiono
Lab technician



Michael Jury, PhD
Lab technician

Sales



**Gabriela Vazquez
Rodrigues, PhD**
Project manager



Franciele Dietrich, PhD
Sales representative



Kristian Moller, PhD
Sales representative

Board of directors



Peter Marcusson
Chairman
Market and BD



Stefan Esbach
Pharma



Magnus Thorarensen
Sales and marketing



Bettina Ernst
Start-up and CRO



Anna Fahlgren
Co-founder

Shareholders

- Founders (Anna Fahlgren and Lasse Jensen) 50,8 %
- Mthor Holding AB (Business angel) 18%
- Almi invest AB (Seed investor) 7%
- Hemex AG (Seed investor) 4,8%
- Avesina Healthcare (Business angel) 3%
- Henrik Lewander Invest AB (Business angel) 4%
- Life science invest Gamma AB 2%
- 7 Business angels incl. LiU Invest 10,4%

Selected awards:



Most innovative CRO 2022 (Healthcare & Pharmaceutical awards)


Top-10 Oncology Solution Providers of 2024 (Medhealth Review)

Top-12 EU Innovation of 2021 (EU Commission)

SKAPA innovation prize (The Swedish Government)

Top-50 Future companies (Techarena Foundation)


OPPORTUNITY



Changing the gameplan for cancer patients

- ✓ Proprietary ZTX[®]PLATFORM predicting the efficiency of any cancer drug for a patient in **only 5 days**.
- ✓ Growing and profitable market within personalized cancer medicine with no current competitors for the ZTX[®]PLATFORM.
- ✓ Proven pre-clinical business model with high-margin products already on the market.
- ✓ Professional and committed team with acceptance and support from scientific and clinical partners and a large network within the pharma industry.
- ✓ CE **certified** product convincingly showing the capability of ZTX[®]PREDICT as a treatment prediction tool.
- ✓ New **automation technologies** are prepared to facilitate the expansion of production and sales.

GET IN TOUCH



Contact information

www.bioreperia.com



Wahlbecksgatan 25
582 13 LINKÖPING SWEDEN



+46 79 33 22 141



anna.erkstam@bioreperia.com

